Cancer Chemother Pharmacol (1990) 25: 395–404

Cancer Chemotherapy and Pharmacology

A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP

Brenda J. Foster[1], Bonnie J. Harding[1], Mary K. Wolpert-DeFilippes[2], Lawrence Y. Rubinstein[3], Kathleen Clagett-Carr[1], and Brian Leyland-Jones[1]

[1] Investigational Drug Branch, [2] Developmental Therapeutics Program, and [3] Biometric Research Branch, National Cancer Institute, Bethesda, Maryland, USA

Summary. The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment.

Introduction

A report by Rosenberg et al. [52] describing the antitumor activity of platinum compounds led to wide-scale clinical investigations of these and other platinum coordination complexes. From these clinical studies, a role for cisplatin in the treatment of a variety of neoplasms was established [34]. The severity of the gastrointestinal and renal toxicities associated with cisplatin administration encouraged trials with schedule manipulations, antiemetic regimens, hydration schema with and without diuretics, and renal prophylaxis such as hypertonic saline and thiosulfate. In addition, interest was stimulated in the development of alternative platinum compounds with a better therapeutic index and a similar or improved antitumor activity spectrum.

Preliminary results against L1210 leukemia and sarcoma 180 in mice [52] demonstrated that the most efficacious platinum compounds had either a *cis* configuration for the chloride groups [platinum(II) coordinated complexes] or were platinum (IV) coordinated complexes. The three properties required for platinum compounds to have antitumor activity are: (a) neutrality; (b) possession of a pair of *cis* leaving groups that have a lability similar to that of the chlorides; and (c) possession of ligands other than the leaving groups [9, 11, 51]. Two cisplatin analogs with these structural characteristics, CBDCA [diammine 1,1 cyclobutane dicarboxylato Pt(II), JM-8, NSC-241240] and CHIP [bis-isopropylamino-*trans*-dihydroxy-*cis*-dichloro Pt(IV), JM-9, NSC-256927], are shown in Fig. 1. Both are undergoing clinical trials sponsored by the National Cancer Institute (NCI). This paper provides a brief review of the preclinical and phase I data on CBDCA and CHIP to present the background for the development of two first-generation platinum coordination complexes and then describes the NCI's planned development of these two agents.

Mechanism of action

Platinum coordination complexes inhibit tumor growth by their effects on DNA replication. The binding of these complexes to DNA is similar to that of bifunctional alkylating agents and has been shown to correlate with cytotoxicity in intact cells [15, 41, 42, 64]. All platinum(II) analogs (including CBDCA) induce DNA shortening and superhelical conformational changes, whereas platinum(IV) compounds (including CHIP) produce DNA degradation [40].

Guanine residues have been shown to be a site of DNA cross-linking [26, 32, 36, 54]. The kinetics of the cisplatin-DNA cross-link formation in L1210 leukemia, previously reported by Zwelling et al., required 12 h drug incubation for maximal cross-link formation. For the much less cytotoxic *trans* isomer, maximal cross-linking occurred by the end of 1 h drug incubation [63]. Other investigators have also reported differences in DNA-protein cross-link kinetics between the *cis* and *trans* isomers [35, 37, 41, 42, 54].

Although both CBDCA and CHIP have been shown to react with DNA [8, 20, 40], Mong et al. [40] reported differences in the types of changes induced in PM-2 DNA by these agents. Cisplatin and CBDCA, both platinum(II) compounds, produced alterations in tertiary DNA conformations but had little effect on linear PM-2 DNA; indeed, superhelical structure was a prerequisite for their cytotoxicity. The activity of both compounds was inhibited by

Offprint requests to: Brian Leyland-Jones, National Cancer Institute, Cancer Therapy Evaluation Program, Investigational Drug Branch, Executive Plaza North, Room 731, Bethesda, MD 20892, USA

CHEMICAL STRUCTURE	COMMON NAME	NSC #	JM #
	Cis Platinum, Cisplatin	119875	—
	CBDCA, Carboplatin	241240	8
	CHIP, Iproplatin	256927	9

Fig. 1. Structures, names, and NSC numbers of cisplatin and two analogs

Table 1. Antitumor activity of cisplatin, CBDCA, and CHIP against the tumor panel

Tumor system	Treatment schedule (i.p.)	Cisplatin:			CBDCA:			CHIP:		
		Dose range[b] (mg/kg)	T/C±SE[a] (%)	Score[c]	Dose range (mg/kg)	T/C±SE (%)	Score	Dose range (mg/kg)	T/C±SE (%)	Score
Murine tumors:										
i.p. B16 melanocarcinoma	q1d, days 1–9	0.2–4.0	178±2	++	12.5–25.0	172± 4	++	12.5	166	++
s.c. CD_8F, mammary tumor	q7d, days 1–29	4.0–12.5	(1±1)	++	50.0–100.0	(8)	++	50.0	(6)	++
s.c. colon 38 tumor	q7d, days 2,9	2.0–16.0	(38±5)	+	100.0–200.0	(33±11)	+	25.0	(46)	–
i.p. L1210 leukemia	q7d, days 1–9	2.0– 4.0	162±2	++	25.0– 64.0	148± 7	+	12.5–25.0	183±14	++
i.v. Lewis lung-carcinoma	q1d, days 1–9	0.5– 2.0	153±6	++	6.3– 25.0	119± 7	–	6.3–12.5	129	–
Human tumor xenografts:										
s.c. CX-1 colon tumor	q4d×3, days 14–22	2–4	(81±8)	–	12.5– 50.0	(63)	–	25.0	(41)	–
s.c. LX-1 lung tumor	q4d×3, days 14	2–8	(69)	–	50.0	(140)	–	25.0	(94)	–
s.c. MX-1 mammary tumor	q4d×3, days 14	4–8	(3)	++	25.0	(43)	–	25.0	(59)	–
Optima i.p. dose, days 1–9			1.6 mg/kg			16 mg/kg			14 mg/kg	

[a] Antitumor activity expressed as the mean optimal T/C (% indicated) (NIH Publication 84 2635)
[b] Dose range for which optimal activity in a dose response was observed. Minimal criteria for activity: % T/C for survival assays – *L1210, B16,* ≥125%; *Lewis lung,* ≥140%; % TC for tumor weight-inhibition assays – CD_8F_1, *colon 38,* ≤42%; *CX-1, LX-1, MX-1,* ≤20%
[c] DN2 criteria for activity: % T/C for survival assays, ≥150%; % T/C for tumor weight-inhibition assays, ≤10% (values in parentheses). ++, Minimal criteria for activity; –, no activity

Table 2. Comparative activity of cisplatin, CBDCA, and CHIP against mouse leukemias

Tumor	Treatment schedule	Cisplatin:		CBDCA:		CHIP:		Reference
		Dose (mg/kg)	Activity	Dose (mg/kg)	Activity	Dose (mg/kg)	Activity	
L1210	Day 1	4–10	157%–186% T/C	32	171% T/C	50	137% T/C	[2, 7, 8, 41,
	Day 1	8	164%–229% T/C	128	150% T/C	32	171% T/C	45, 46]
	Days 1–9	2/day	157%–285% T/C	64	157% T/C	16/day	207% T/C	
	Days 1–9 or Days 1, 5, 9	1.6–2.4/day	186%–257% T/C	25/day	152% T/C	25/day	191% T/C	
L1210/CDDP	Day 1	4–8	94%–131% T/C	120	113% T/C	32	118% T/C	[46]
L1210 *in vivo* → *in vitro*	Day 1	9	Surviving fraction = 50%[a]	336	Surviving fraction = 50%[a]	135	Surviving fraction = 50%[a]	[27]
P388	Days 1–9	–	–	25	152% T/C	18	202% T/C	[7, 8]
	Days 1, 5, 9	–	–	–	–	50	154% T/C	

[a] In vitro colony formation assay. Shown is the dose that caused a 50% reduction in the colony formation of tumor cells in vitro following treatment of tumor-bearing mice. %T/C, Median survival time of drug-treated tumor-bearing mice compared with that of mice treated with vehicle only. Drugs were given i.p.

sodium chloride. CHIP, a platinum(IV) compound, caused breakage of covalently closed, circular PM-2 DNA; this breakage was not inhibited by sodium chloride. This suggests involvement of the axial *trans* bonds rather than the equatorial *cis* bonds [40]. In addition, the concentration of CHIP required to produce DNA damage was higher than that required for cytotoxicity [40], suggesting that DNA breakage may not be the primary mechanism of cytotoxicity.

Antitumor activity

CBDCA and CHIP have been tested for antitumor activity against many in vitro and in vivo tumor models, including human tumor xenografts. Comparative results obtained with the analogs and cisplatin at optimal doses against tumors used in a preclinical screen at the NCI are shown in Table 1 [60, 61]. These data are the results of screening carried out under the auspices of the Developmental Therapeutics Program (Division of Cancer Treatment, NCI, Bethesda, Md). Cisplatin showed the broadest ac-

Table 3. Toxicity of cisplatin, CBDCA, and CHIP after a single i.v. dose in male F344 rats

	Cisplatin mg/kg (mg/m^2)	CBDCA mg/kg (mg/m^2)	CHIP mg/kg (mg/m^2)
LD_{10}	6 (36)	52.5 (313.2)	33.4 (200.4)
LD_{50}	8 (48)	60.9 (365.4)	39.0 (234.0)
$\frac{LD_{50}}{LD_{10}}$[a]	1.3	1.2	1.2
$\frac{LD_{50}}{LD_{50}}$[b]	–	7.6	4.9

LD_{10} or LD_{50} is the dose that produced lethality in 10% or 50%, respectively, of the rats treated (data from [58])

[a] $\frac{LD_{50}\text{ compound in mg/kg}}{LD_{10}\text{ compound in mg/kg}}$ = toxicity quotient

[b] $\frac{LD_{50}\text{ analog in mg/kg}}{LD_{50}\text{ cisplatin in mg/kg}}$ = potency ratio

Table 4. (*a*) Comparative toxicity of cisplatin, CBDCA, and CHIP after a single i.v. injection in male F344 rats

Parameter	Cisplatin	CBDCA	CHIP
Hematocrit	1	3	2
WBC	3	2	3
BUN	3	1	1
Creatinine	3	1	1
SGPT	1	1	1
Body weight loss	3	1	2
Histopathology:			
Renal	4	1	3
Lymphatic	4	1	4
Hematopoietic	3	4	3
Gastrointestinal	4	1	1
Total score:	30	16	21

(*b*) Scoring used for comparative toxicity of platinum compounds after single-dose administration

Parameter	Scoring system and definitions
Hematocrit, WBC	1 = <20% decrease 2 = 20%–50% decrease 3 = >50% decrease
BUN, creatinine, SGPT	1 = <50% decrease 2 = 50%–200% increase 3 = >200% increase
Body weight loss	1 = no weight loss (maybe slowing of growth) 2 = <10% (or <15% serial bleeding) weight loss 3 = ≥10% (or >15% serial bleeding) weight loss
Histopathology	1 = no lesions 2 = mild lesions in few animals 3 = lesions of moderate to marked severity 4 = lesions of marked to extreme severity

WBC, leukocyte count; BUN, blood urea nitrogen; SGPT, glutamic pyruvic transaminase
Data from [58]

tivity spectrum, with significant activity against i.v. Lewis lung carcinoma and s.c. human mammary xenograft [60, 61], neither of which were affected by CBDCA or CHIP. Both cisplatin and CBDCA showed a similar level of activity against s.c. colon 38, whereas CHIP showed no activity. Cisplatin and CHIP showed quantitatively better activity against i.p. L1210 than did CBDCA [60, 61].

The results of comparative experiments in mouse leukemias are summarized in Table 2 [4, 9, 10, 29, 45, 49, 50, 58]. The L1210 in vivo and in vitro results clearly indicate that cisplatin has the highest potency, followed by CHIP, with CBDCA being the least potent [29]. An L1210 line made resistant in vitro to cisplatin (L1210/CDDP) demonstrated cross-resistance to CBDCA and CHIP [49].

Toxicology

Comparative toxicologic studies showed CBDCA and CHIP to be less potent than the parent compound, as evidenced by the defined toxic doses shown in Table 3 [58]. The severity of myelosuppression, nephrotoxicity, and gastrointestinal toxicity caused by the parent compound was qualitatively different from that observed after treatment with the two analogs, as shown in Table 4 [29, 45, 50, 58]. Both CBDCA and CHIP produced more hematologic toxicity than did cisplatin, but they caused much less renal toxicity than the parent drug. Cisplatin produced more severe histopathologic lesions in the gastrointestinal tract than did either analog.

In summary, toxicologic studies showed the two analogs to be less potent than cisplatin, and, although the same organ systems (hematologic, renal, and gastrointestinal) were affected by all three compounds, the patterns of toxicity were different. The analogs consistently showed less renal and gastrointestinal toxicity but more hematopoietic toxicity than did cisplatin.

Clinical studies results

Phase I trials

Comparative results from phase I studies of cisplatin, CBDCA, and CHIP in adults are shown in Table 5 [5–7, 12–14, 17, 22, 24, 25, 27, 31, 33, 46, 47, 53, 55, 57, 59]. Based on the total dose (in milligrams) tolerated for each drug, cisplatin is the most potent; CHIP, intermediate; and CBDCA, the least potent. CBDCA and CHIP differed from cisplatin in the relative severity of their gastrointestinal, neurologic, renal, and hematologic side effects. Hematologic effects, especially thrombocytopenia, were dose-limiting for CBDCA and CHIP [5, 6, 12, 13, 17, 22, 24, 27, 31, 46, 47, 53, 55, 57, 59], whereas renal, hematologic, and gastrointestinal effects were frequently dose-limiting for cisplatin [12, 22, 53, 57]. Diarrhea was reported from studies of CHIP, but it was not dose-limiting [5, 13, 17, 24, 47]. Renal toxic effects observed in studies of CBDCA and CHIP occurred in patients who had preexisting renal disease or a concomitant nephrotoxic event [6, 14, 17, 27, 47]. No new neurologic toxicity was found with administration of the analogs; however, exacerbations of preexisting neurologic defects were observed following treatment with CBDCA [6, 14, 27, 55]. Antitumor effects were reported from the phase I trials of each compound, particularly in patients with ovarian carcinoma. In summary, less renal toxicity was seen with the analogs and hematologic toxic effects were dose-limiting in phase I testing of CBDCA and CHIP, confirming the results seen in preclinical toxicologic studies.

Clinical pharmacokinetics

The clinical pharmacokinetic parameters of the three compounds after i.v. single-dose administration are summarized in Table 6. Total and filterable (free, non-protein-bound) platinum values were determined using flameless atomic absorption spectrophotometry [18, 19, 21, 24, 43]. Following CBDCA or CHIP administration, the plot of the plasma levels for either total or filterable platinum was most often described as biexponential. The initial half-life ($t_{1/2}$) was usually <1 h, whereas the terminal half-life ($t_{1/2}\,\beta$) ranged from 7 h to over 5 days. This biexponential pattern was not reported for cisplatin. Thus far, no major pharmacokinetic differences have been observed that explain the differences in clinical potency and toxicity of these three analogs.

Developmental plans

The simultaneous clinical development of CBDCA and CHIP has stimulated many questions regarding the relative utility of each with respect to the other as well as to cisplatin. The scientific questions center around the relative therapeutic index (antitumor effects vs acute and chronic toxic side effects) of each compound relative to the others. This section describes some of the clinical developmental plans for these two analogs as well as giving specific illustrative examples for each of the three main disease categories.

Disease-oriented strategy. To incorporate the concept of *relative therapeutic index* into the phase II and phase III developmental plans, diseases were divided into three major categories according to cisplatin responsiveness and whether or not cisplatin was an important component of currently used standard treatment of the advanced disease. Illustrative examples of these disease categories are given in Table 7 and include the following:

A Cisplatin-sensitive diseases, where standard therapy incorporating cisplatin is curative; examples include germ-cell tumors and epithelial ovarian carcinomas. In this category, it is highly likely that CBDCA and CHIP would have some antitumor activity; in fact, hints of tumor responsiveness were seen in patients with ovarian carcinoma entered in the phase I trials. In this category, the usefulness of a traditional phase II trial was questioned. A phase II trial entering 30–40 patients would delineate an analog's antitumor activity with such broad confidence limits that it would not be possible to determine the activity relative to that of the parent compound. Therefore, the plan was to move directly from phase I testing to phase III comparative trials.

An illustrative example for this category is provided by a comparative trial of one analog with the parent compound. Patients with advanced ovarian carcinoma who had not received prior chemotherapy were randomized to receive a combination of either CBDCA plus cyclophosphamide or cisplatin plus cyclophosphamide [1]. The cyclophosphamide dose (mg/m^2) was the same in each combination. Preliminary results show equivalent activity;

Table 5. Comparative adult phase I studies of cisplatin, CBDCA, and CHIP

Schedule	Cisplatin:				CBDCA:				CHIP:			
	Maximal dose(s) each day (mg/m^2)	Major toxicities			Maximal dose(s) each day (mg/m^2)	Major toxicities			Maximal dose(s) each day (mg/m^2)	Major toxicities		
		Dose-limiting	Others	Reference		Dose-limiting	Others	Reference		Dose-limiting	Others	Reference
Single dose	200, 100	Renal Nausea & vomiting	RBC, WBC, plts Hearing, loss, tinnitus Hyperuricema	[21, 50]	520, 550, 440, 600	↓plts	Nausea & vomiting ↓WBC, RBC Renal Malaise Neuropathy	[4, 24, 26, 29]	350, 350	↓plts	↓WBC, RBC Nausea & vomiting Diarrhea Hypersensitivity (rash)	[3, 11]
Twice weekly × 2–4 week	15, 60	WBC, RBC, plts Nausea & vomiting	Renal Tinnitus	[5, 53]	–	–	–	–	–	–	–	–
Daily × 5	40, 24, 15	Renal	Nausea & vomiting ↓RBC, WBC, plts Tinnitus, hearing loss Heart failure with conduction defects	[21, 50, 53]	125, 99	↓WBC, plts	Nausea & vomiting ↓RBC Renal Paresthesias Myalgia, arthralgia	[54]	65, 45	↓plts	↓WBC, RBC Renal Nausea & vomiting Diarrhea Hypersensitivity (rash)	[16, 43]
Weekly × 4	55	↓WBC, plts	Renal Nausea & vomiting Tinnitus Hypersensitivity	[10]	150	↓plts	Renal	[42]	95	↓plts	↓WBC, RBC Nausea & vomiting Diarrhea	[23]
Bolus q4d until toxicity	~80	↓WBC, plts renal	Nausea & vomiting Hearing loss	[31]	–	–	–	–	–	–	–	–
24-h continuous infusion	–	–	–	–	500, 320	↓plts	Nausea & vomiting Hearing loss ↓Mg ↓RBC Renal	[12, 29]	–	–	–	–

RBC, red blood cells; WBC, white blood cells; plts, platelets; ↓, decreased; Mg, serum magnesium

Table 6. Clinical pharmacokinetic characteristics determined by atomic absorption spectrophotometry

	Cisplatin:		CBDCA:		CHIP:	
	Total	Filterable	Total	Filterable	Total	Filterable
Single dose	70–100 mg/m²		150–500 mg/m²		20–350 mg/m²	
Curve of plasma levels	Triexponential Biexponential Biexponential	Monoexponential Monoexponential Biexponential	– Biexponential	Biexponential Biexponential	Biexponential	Monoexponential at low doses, biexponential at high doses[a]
Initial $t_{1/2}$	20 min 17.5 min 23 min	20–30 min 23.6 min 8–10 min	– 98 min	5.4 min 87 min	0.96 h	1.75 h (low doses) 1.08 h (high doses)
Terminal $t_{1/2}$	>24 h 30.5 h 67 h	– – 40–45 min	– 6.7–>24 h	131 min 354 min	64 h	32.3 h (high doses)
% Urinary excretion of dose	– 45% in 48 h 23% in 24 h	– – –	66% in 24 h 65% in 24 h	– –	15–61% in 24 h	–

however, less toxicity was reported for patients treated with the CBDCA-containing combination. The investigators concluded improved efficacy for the CBDCA combination in these patients. Further discussion of these plans is presented in *Statistical and other considerations* (below).

B Cisplatin-sensitive diseases, where standard therapy in advanced disease has a major palliative effect; (examples include small-cell lung, urinary bladder, uterine cervical, and head and neck carcinomas. Analog development for this group of diseases is the most difficult. One approach advocates a traditional phase II trial for this group of patients to establish a minimal level of activity before proceeding with major phase III trial(s), especially if hints of antitumor activity are seen in patients with these tumors in phase I trials. Although the determination of this "minimal level" requires 40 patients or more, many investigators feel that this is an ethical necessity before proceeding to a phase III trial requiring 300–700 patients, where most patients achieve palliation rather than cure of their disease.

In practice, the developmental plans have proven to be different for each tumor type in this disease category. For small-cell lung carcinoma, traditional phase II trials were used, followed by a phase III trial comparing one analog against the parent compound. For urinary bladder and uterine cervical carcinomas, randomized phase II trials of the analogs were pursued with the endpoint of determining whether either analog was significantly superior to the other, thereby enabling the exclusion of a major difference in antitumor activity with acceptable confidence limits. Thus, only one analog need be investigated in comparative phase III trials against the parent compound with an acceptable risk of *not* having picked the "wrong" analog for comparison. For head and neck cancer, one investigator chose to undertake a randomized addition-type phase III trial with treatment arms of methotrexate vs methotrexate plus one analog (CBDCA).

A review of the trial results for each disease is beyond the scope of this report. However, published results from the use of these analogs in the treatment of patients with advanced carcinoma of the uterine cervix provide a general illustration for this group. The study began as a randomized phase II trial of the analogs [2, 38] and was continued to phase III endpoints [39] when an objective response rate (complete plus partial responses) of ›20% was observed in both arms at the completion phase II. At the end of the phase III trial, the investigators concluded that neither analog appeared to be as active as the parent compound against squamous carcinoma of the uterine cervix [39].

Table 7. Advanced disease sensitivity to cisplatin-containing regimens

Sensitivity	Examples
A. Sensitive and curative	Germ-cell tumors Epithelial ovarian carcinoma
B. Sensitive with major palliative effect	Small-cell lung carcinoma Bladder carcinoma Head and neck carcinoma Uterine cervical carcinoma
C. Resistant or no major palliative effect	Non-small-cell lung carcinoma Colorectal carcinoma Breast carcinoma Melanomas

C Diseases that are often not palliated by treatment with cisplatin-containing regimens in advanced disease include melanoma and colorectal, breast, and non-small-cell lung carcinomas. The developmental plans for this category were the most straightforward. A traditional phase II trial of each analog in minimally pretreated patients was planned to determine antitumor efficacy. However, in diseases where many patients were available for clinical trials, randomized phase II trials were carried out in an attempt to select the more active agent before entering definitive phase III trials. If the analog demonstrated efficacy in the initial 14–20 patients entered, an estimate of the level of activity in 40–80 patients was determined.

Published results from a randomized phase II in patients with non-small-cell carcinoma of the lung showed



Fig. 2. A scheme of possible stepwise clinical evaluations of two cisplatin analogs

the activity of both analogs to have overlapping 95% confidence limits (CBDCA, 7%–25%; CHIP, 1%–13%) with similar survival [28]. Although the activity was modest, the investigators recommended further studies of CBDCA as a component of combination chemotherapy.

Statistical and other considerations

For the cisplatin-responsive diseases (curative and major palliative effect), the optimal trial design to answer the questions of relative therapeutic index is a three-way, randomized phase III trial using these compounds at optimal doses. The trial must be designed to detect a significant decrease in toxicity and, more importantly, to ensure that no significant decrease in survival occurs. For ovarian cancer, where the 2-year survival is roughly 60%, this would require 160 patients per arm to ensure that a decrease to 45% 2-year survival would be detected with type I and II error limits of 0.10 [16]. For testicular cancer, where the curability in advanced disease is ›80%, the problem is even more difficult, because one must ensure the detection of a 10% decrease in this rate using the same type I and II error limits of 0.10. Testicular cancer is not a common malignancy, and the three-arm, randomized trial would require 265 patients per arm. Obviously, the three-arm, randomized trial is not practical for all cisplatin-sensitive diseases. An alternative approach enables the accomplishment of indirect comparisons in a two-stage fashion (Fig. 2, section *A*). The initial part of the evaluation consists of randomized phase II studies with CBDCA and CHIP in selected cisplatin-sensitive (Table 7, category *B*) and -insensitive diseases (Table 7, category *C*). If one analog exhibited a clear advantage in the initial studies, that analog would be used in the definitive phase III studies and the other could be eliminated from further trials in those disease sites.

The number of patients required for each two-arm, randomized phase II study is dependent on the anticipated activity of the compounds. The diseases in which a higher response rate is anticipated require higher patient numbers per arm to ensure a 90% probability of detecting a 15% difference in the rates. Where response rates are 15%–20%, 25–30 patients per arm are required, and where they are ⩾30%, 35–40 patients are required [56].

A different set of studies are shown in section *B* of Fig. 2 to illustrate another alternative stepwise approach to determine the relative therapeutic indices. This approach uses two initial-stage studies to plan the definitive study. There are three possible outcomes to the initial studies. If both analogs are superior to cisplatin, the definitive study will involve only the analogs. If one analog is superior in one study but cisplatin is superior in the other, the lesser analog could be eliminated from the definitive study if the apparent difference in the therapeutic indices is significant and the test conditions in the two initial studies are the same. If neither analog is superior, sufficient numbers of patients must be accrued to each arm of the initial studies to yield a definitive answer.

In the stepwise evaluations of CBDCA and CHIP planned by the NCI, the two-stage design (section *A*) was used whenever possible because (a) the preclinical results showed more similarities between the two analogs than between either analog and cisplatin; and (b) the section-*A* design required one rather than two studies at the phase II level, thus simplifying the planning. The notable exception to using this design was the planning of a three-way, ran-

domized definitive trial in previously untreated patients with advanced ovarian cancer after the completion of the phase I CBDCA and CHIP trials. It was felt that phase II trial results were not needed to plan the definitive trial in this disease site because of the number of ovarian cancer patients who had been treated in phase I trials and had shown a major response (complete or partial).

Conclusion

The broad spectrum of antitumor responsiveness to cisplatin and the high incidence of severe gastrointestinal, renal, and neurologic toxicity have spurred the development of a number of first-generation cisplatin analogs. The majority of these analogs are characterized by: (a) a preclinical antitumor spectrum similar to that of cisplatin, (b) quantitatively less preclinical renal and gastrointestinal toxicity and (c) quantitatively more bone marrow toxicity than cisplatin. CBDCA and CHIP are two such analogs currently undergoing clinical trials for determination of the antitumor and toxicity spectrum of each relative to the other and, ultimately, to cisplatin. Because of differences in their mechanism of action and antitumor activity, both compounds underwent phase I testing, where objective responses were reported from trials with each compound. Sufficient patient numbers for a particular disease, ethical considerations when a palliative effect rather than a cure was expected, and statistical considerations were factors in forming the proposed approach to the clinical development of each analog. The proposed developmental strategy incorporated trial designs based on disease responsiveness to cisplatin for assessment of relative disease-specific antitumor activity. In particular, the toxicity results from comparative phase III trials using the analog(s) and cisplatin at their maximal doses (alone or in fixed-dose drug combinations) will enable assessments of relative tolerance. Using the combined results for relative disease-specific antitumor activity and relative tolerance, relative therapeutic index may be assessed. Using the methodology outlined here, we feel that the best analog for each particular disease may be determined, providing a firm foundation for disease-specific combination protocols and future cisplatin analog development.

Acknowledgements. The authors would like to thank Mr. Wayne P. Henry and Ms Sandi Rife for their expert assistance in the preparation of this manuscript and Dr. Silvia Marsoni for helpful discussions during the early stages of formulating the developmental plans.

References

1. Alberts D, Green S, Hannigan E, O'Tools R, Mason-Liddil N, Surwit E, Stock-Novack D, Goldberg R, Malviya V, Nahhas W (1989) Improved efficacy of carboplatin (Carbo-P)/cyclophosphamide (CPA) vs cisplatin (CisP)/CPA: preliminary report of a phase III, randomized trial in stages III–IV, suboptimal ovarian cancer (OV CA). Proc Am Soc Clin Oncol 8: 151
2. Arseneau JC, Hatch K, Stehman F, Blessing J (1985) Phase II study of carboplatin in advanced squamous cell carcinoma of cervix. Proc Am Soc Clin Oncol 4: 120
3. Basolo F, Pearson RG (1962) The *trans* effect in metal complexes. Prog Inorg Chem 4: 381–453
4. Bradner WT, Rose WC, Huftalen JB (1980) Antitumor activity of platinum analogs. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin – current status and new developments. Academic, New York, pp 171–182
5. Bramwell VHC, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A (1985) Activity of JM9 in advanced ovarian cancer: a phase I–II trial. Cancer Treat Rep 69: 409–416
6. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with *cis*-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140–147
7. Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high dose *cis*-dichlorodiammine-platinum II with forced diuresis. Cancer Treat Rep 61: 367–370
8. Cleare MJ, Hoeschele JD (1973) Studies on the antitumor activity of group VIII transition metal complexes: I. Platinum (II) complexes. Bioinorg Chem 2: 187–210
9. Cleare MJ, Hydes PC, Malerbi BW, Walkins DM (1978) Antitumor platinum complexes: relationships between chemical properties and activity. Biochimie 60: 835–850
10. Cleare MJ, Hydes PC, Hepburn DR, Malerbi BW (1980) Antitumor platinum complexes: structure-activity relationships. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin-current status and new developments. Academic, New York, pp 149–170
11. Connors TA, Cleare MJ, Harrap KR (1979) Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 63: 1499–1502
12. Corder MP, Elliott TE, Bell SJ (1977) Dose limiting myelotoxicity in absence of significant nephrotoxicity with a weekly out-patient schedule of *cis*-platinum (II) diamminedichloride. J Clin Hematol Oncol 7: 645–651
13. Creaven PJ, Madajewicz S, Pendyala L, Mittleman A, Pontes E, Spaulding M, Arbuck S, Solomon J (1983) Phase I clinical trial of *cis*-dichloro-*trans*-dihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep 67: 795–800
14. Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) Phase I and pharmacokinetic study of diammine cyclobutane dicarboxylatoplatinum (NSC-241240). Cancer Res 43: 4470–4473
15. Ducore JM, Erickson LC, Zwelling LA, Laurent G, Kohn KW (1982) Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with *cis*-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 42: 897–902
16. Fleiss JL (1981) Statistical methods for rates and proportions. Wiley and Sons, New York
17. Ginsberg S, Lee F, Issell B, Poiesz B, Rudolph A, Louie A, Bradley E, Tinsley R, DiFino S, Scalzo A, Gullo T, Lerner M, Palmer N, Fitzpatrick A, Comis R (1983) A phase I study of *cis*-dichloro-*trans*-dihydroxy-bis (isopropylamine) platinum IV (CHIP) administered by intravenous bolus daily for 5 days. Proc Am Soc Clin Oncol 2: 35
18. Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics of *cis*-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351–357
19. Gullo JJ, Litterst CL, Maquire PJ, Sikic BI, Hoth DF, Woolley PV (1980) Pharmacokinetics and protein binding of *cis*-dichlorodiammine platinum(II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 5: 21–26
20. Harder HC, Rosenberg B (1970) Inhibitory effects of antitumor platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int J Cancer 6: 207–216
21. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics of *cis*-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693–1697

22. Higby DJ, Wallace HJ Jr, Holland JF (1973) *cis*-Diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 57: 459–463
23. Hill JM, Loeb E, Pardue A, Khon A, King JJ, Aleman C, Hill NO (1979) Platinum analogs of clinical interest. Cancer Treat Rep 63: 1509–1513
24. Himmelstein KJ, Patton TF, Beld RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29: 658–664
25. Joss RA, Kaplan S, Goldhirsh A, Sessa C, Brunner KW, Cavalli F (1984) A phase I trial of *cis*-diammine-1,1-cyclobutane dicarboxylate platinum(II) (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 2: 297–304
26. Kelman AO, Peresie HJ (1979) Mode of DNA binding of cisplatinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed. Cancer Treat Rep 63: 1445–1452
27. Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC (1986) Phase I clinical trial and pharmacokinetics of carboplatin (NSC-241240) by single monthly 30 minute infusion. Cancer 57: 222–225
28. Kreisman H, Ginsburg S, Propert KJ, Richards F, Graziano S, Green M (1987) Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 71: 1049–1052
29. Lelieveld P, Van der Vijgh WJF, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A (1984) Preclinical studies on toxicity, antitumor activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20: 1087–1104
30. Lenaz I, Canetta R, Hilgard P, Florentine S, Bedogni P (1982) The selection of new cisplatin analogs for clinical evaluation. Chemioterapia 1: 90–97
31. Leyvraz S, Ohnuma T, Lassus M, Holland J (1985) Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 3: 1385–1392
32. Lippard SJ (1982) New Chemistry of an old molecule: *cis*-$[Pt(NH_3)_2Cl_2]$. Science 218: 1075–1082
33. Lippman AJ, Helson C, Helson L, and Krakoff IH (1973) Clinical trials of *cis*-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 57: 191–200
34. Loeher PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100: 704–713
35. Macquet JP, Theophamides T (1975) DNA platinum interactions in vitro with *trans*- a *cis*-Pt $(NH_3)_2Cl_2$. Bioinorg Chem 5: 59–66
36. Mallard MM, Macquet JP, Theophamides T (1975) X-ray photoelectron spectroscopy of DNA Pt complexes. Evidence of $O^6(Gua)N_7(Gua)$ chelation of DNA with *cis*-chlorodiammineplatinum(II). Biochim Biophys Acta 402: 166–170
37. Mansy S, Rosenberg B, Thompson AJ (1973) Binding of *cis*- and *trans*-dichlorodiammineplatinum(II) to nucleosides: I. Location of the binding sites. J Am Chem Soc 95: 1633–1640
38. McGuire W, Blessing J, Stehman F, Hatch K (1985) Phase II study of CHIP in advanced squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 4: 121
39. McGuire WP, Arseneau JC, Blessing JA, Given FT, Hatch KD, Creasman WT, Di Saia PJ, Teng NN (1988) Randomized comparison of carboplatin (CP) and iproplatin (IP) in advanced squamous carcinoma of the uterine cervix (SCUC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 7: 135
40. Mong S, Huang CH, Prestayko AW, Crooke ST (1980) Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo. Cancer Res 40: 3318–3324
41. Pascoe JM, Roberts JJ (1974) Interactions between mammalian cell DNA and inorganic platinum compounds – I. Biochem Pharmacol 23: 1345–1357
42. Pascoe JM, Roberts JJ (1974) Interactions between mammalian cell DNA and inorganic platinum compounds – II. Biochem Pharmacol 23: 1359–1366
43. Penyala L, Greco W, Cowens JW, Madajewicz S, Creaven PJ (1983) Pharmacokinetics of *cis*-dichloro-*trans*-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer. Cancer Chemother Pharmacol 11: 23–28
44. Peyrot V, Briand C, Braguer CO, Chellvet-Monges AM, Sari JC (1983) Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro Cancer Treat Rep 67: 641–646
45. Prestayko AW, Bradner WT, Huftalen JB, Rose WG, Schurig JE, Cleare MJ, Hayes PC, Crooke ST (1979) Antileukemic (L1210) activity and toxicity of *cis*-dichlorodiammineplatinum(II) analogs. Cancer Treat Rep 63: 1503–1508
46. Priego V, Luc V, Bonnem E, Rahman A, Smith F, Schein P, Woolley P (1983) A phase I study of pharmacology of diammine-(1,1)-cyclobutane dicarboxlato-(2-1-0)-platinum (CBDCA) administered on a weekly schedule. Proc Am Soc Clin Oncol 2: 30
47. Ribaud P, Goveia J, Dorval T, Misset JL, Machover D, Gastiaburu J, Schwarzenberg L, Mathe G (1984) Phase I study of CHIP. Invest New Drugs 2 (1): 103
48. Roberts JJ, Pasco JM (1972) Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds (letter). Nature 235: 282–284
49. Rose WC, Bradner WT (1984) Experimental antitumor activity of platinum coordination complexes. In: Hacher MP, Douple EB, Krakoff IH (eds) Platinum coordination complexes in cancer chemotherapy. Martin Nijhoff, Boston, pp 228–239
50. Rose WC, Schurig JE, Huftalen JB, Bradner WT (1982) Antitumor activity and toxicity of cisplatin analogs. Cancer Treat Rep 66: 135–146
51. Rosenberg B (1979) Anticancer activity of *cis*-dichlorodiammine-platinum(II) and some relevant chemistry. Cancer Treat Rep 63: 1433–1438
52. Rosenberg B, Van Camp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222: 385–386
53. Rossof AH, Slayton ER, Perlia CP (1972) Preliminary clinical experience with *cis*-diamminedichloroplatinum(II) (NSC-119875, CACP). Cancer 30: 1451–1456
54. Royer-Pokora B, Gordon LK, Haseltine WA (1981) Use of exonuclease III to determine the site of stable lesions in defined sequences of DNA: the cyclobutane pyrimidine dimer and *cis*- and *trans*-dichlorodiammine platinum II examples. Nucleic Acids Res 9: 4595–4609
55. Rozencweig M, Nicaise C, Beer M, Crespeigne N, Van Rijmenant M, Lenaz L, Kenis Y (1983) Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol 1: 621–626
56. Simon R, Wittes RE, Ellenberg SE (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375–1381
57. Talley RW, O'Bryan RM, Gutterman JU, Brownlee RW, McCredie E (1973) Clinical evaluation of toxic effects of *cis*-diamminedichloroplatinum (NSC-119875) – phase I clinical study. Cancer Chemother Rep 57: 465–471
58. U.S. Department of National Technical Information Services Reports: PB 84 163740 "A toxicologic evaluation of five platinum-containing compounds: NSC-119875, NSC-224964, NSC-241240, NSC-250427, and NSC-256927 in dogs." (MRI-KC-PT-3899-79-19); PB 84 163757 "Amendment to Report MRI-KC-PT-3899-79-19. 'A toxicological evaluation of five platinum-containing compounds: NSC-119875, NSC-224964, NSC-241240, and NSC-256927 in dogs.'" (MRI-KC-PT-3899-81-29); PB 82 165028 "Preclinical toxicologic evaluation of diammine [1,1-cyclobutanedi-carboxylato(2-)*O,O'*]-(*SP*-4-2) platinum (NSC-241240) given intravenously to mice." (MRI-KC-PT-7150-81-1); PB 297710/AS "Renal toxicity study of NSC 241240 and NSC-

271674." (IITRI-Tox-241240/271674-78-15); PB 288368/AS "Renal toxicity study of NSC-250427 and NSC-256927 in the rat." (IITRI-Tox-250427/256927-78-14)
59. Van Echo DA, Egorin MJ, Whitacre MY, Olman EA, Aisner J (1984) Phase I and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep 68: 1103–1114
60. Wolpert-DeFillipes MK (1979) Antitumor activity of *cis*-dichlorodiammine-platinum(II). Cancer Treat Rep 63: 1453–1458
61. Wolpert-DeFillipes MK (1980) Antitumor activity of cisplatin analogs. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin-current status and new developments. Academic, New York, pp 183–191
62. Zwelling LA, Kohn KW (1979) Mechanism of action of *cis*-dichlorodiammine-platinum(II). Cancer Treat Rep 63: 1439–1444
63. Zwelling LA, Kohn KW, Ross WE, Ewig RAG, Anderson T (1978) Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with *cis*- and *trans*-diamminedichloroplatinum(II)
64. Zwelling LA, Anderson T, Kohn KW (1979) DNA protein and DNA interstrand cross-linking by *cis*- and *trans*-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39: 365–369

Received 11 November 1988/Accepted 2 June 1989